Currently, there are 1.28B common shares owned by the public and among those 1.28B shares have been available to trade.
The company’s stock has a 5-day price change of 6.78% and -4.60% over the past three months. MDT shares are trading 6.72% year to date (YTD), with the 12-month market performance down to -2.11% lower. It has a 12-month low price of $75.96 and touched a high of $92.68 over the same period. MDT has an average intraday trading volume of 6.16 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 5.10%, 1.12%, and 1.32% respectively.
Institutional ownership of Medtronic Plc (NYSE: MDT) shares accounts for 84.58% of the company’s 1.28B shares outstanding.
It has a market capitalization of $109.31B and a beta (3y monthly) value of 0.84. The stock’s trailing 12-month PE ratio is 26.02, while the earnings-per-share (ttm) stands at $3.28. The company has a PEG of 4.53 and a Quick Ratio of 1.39 with the debt-to-equity ratio at 0.58. Price movements for the stock have been influenced by the stock’s volatility, which stands at 2.60% over the week and 1.65% over the month.
Analysts forecast that Medtronic Plc (MDT) will achieve an EPS of 1.36 for the current quarter, 1.61 for the next quarter and 5.84 for current fiscal year. The lowest estimate earnings-per-share for the quarter is 1.35 while analysts give the company a high EPS estimate of 1.35. Comparatively, EPS for the current quarter was 1.3 a year ago. Earnings per share for the fiscal year are expected to increase by 4.84%, and 7.16% over the next financial year. EPS should grow at an annualized rate of 5.75% over the next five years, compared to -4.12% over the past 5-year period.
Looking at the support for the MDT, a number of firms have released research notes about the stock. RBC Capital Mkts stated their Outperform rating for the stock in a research note on October 10, 2024, with the firm’s price target at $98-$105. Oppenheimer coverage for the Medtronic Plc (MDT) stock in a research note released on August 21, 2024 offered a Perform rating with a price target of $94. UBS was of a view on August 15, 2024 that the stock is Neutral, while Stifel gave the stock Hold rating on August 14, 2024, issuing a price target of $100- $85. Goldman on their part issued Sell rating on May 30, 2024.
